all glp-1 medications Indications for GLP-1/GIP RA Summary Sheet and Beyond! Market Overview: GLP-1 Agonists and

As a formulator and researcher with a deep interest in nutrient metabolism and cellular health, Ive been following this closely

Cardiovascular risk reduction Wegovy is now used to assist in reducing the risk of even worse forms of cardiovascular issues in high risk heart disease patients and for impurpose weight or obesity

In a statement today, Tummino said of the second Lilly partnership: We are excited to collaborate with Lilly on another program, combining our discovery capabilities with their metabolic disease expertise to bring a much-needed new treatment to people with obesity and make a meaningful difference in their lives. $55M upfront Lilly agreed to pay Nimbus $55 million in upfront and near-term payments tied to achieving milestones

27 In CY-5 experiments, replacing Arg 18 from GCG with Ala simultaneously improved both the GLP-1 and GIP activity